CLAIMS

1. Use of an inhibiting agent in the preparation of a pharmaceutical composition for preventing, inhibiting or treating a *P. gingivalis* infection in a subject, wherein the inhibiting agent prevents, inhibits or reduces a *P. gingivalis* biofilm and is an inhibitor of an enzyme.

2. Use of an inhibiting agent in the preparation of a pharmaceutical composition for preventing, inhibiting or treating periodontal disease in a subject, wherein the inhibiting agent prevents, inhibits or reduces a *P. gingivalis* biofilm and is an inhibitor of an enzyme.

3. The use of claim 1 or claim 2, wherein the enzyme is a metabolic enzyme.

4. The use of any one of claims 1 to 3, wherein the enzyme is involved in organic acid metabolism.

5. The use of any one of claims 1 to 4, wherein the inhibiting agent is an inhibitor of
fumarate reductase activity.

6. The use of any one of claims 1 to 5, wherein the enzyme is a fumarate reductase.

7. The use of claim 6, wherein the fumarate reductase corresponds to accession number AAQ66643~~AAQ66642~~ or AAQ66642~~AAG66643~~.

8. The use of any one of claims 1 to 7, wherein the inhibiting agent is selected from the group consisting of oxantel, morantel and thiabedazole.

9. The use of claim 8, wherein the inhibiting agent is oxantel.

10. The use of claim 8, wherein the inhibiting agent is morantel.

11. The use of claim 8, wherein the inhibiting agent is thiabedazole.

12. The use of any one of claims 1 to 11, further comprising the use of an antibiotic.

13. A composition for use in the prevention, inhibition or treatment of *P. gingivalis* infection, the composition comprising an inhibiting agent that prevents, inhibits or reduces a *P. gingivalis* biofilm and is an inhibitor of an enzyme.

14. A composition for use in the prevention, inhibition or treatment of periodontal disease, the composition comprising an inhibiting agent that prevents, inhibits or reduces a *P. gingivalis* biofilm and is an inhibitor of an enzyme.

15. The composition of any one of claims 13 to 14, wherein the inhibiting agent is an inhibitor of fumarate reductase activity.

16. The composition of any one of claims 13 to 15, wherein the enzyme is a fumarate reductase.

17. The composition of any one of claims 13 to 16, wherein the fumarate reductase corresponds to accession number AAQ66643~~AAQ66642~~ or AAQ66642~~AAG66643~~.

18. The composition of any one of claims 13 to 17, wherein the inhibiting agent is selected from the group consisting of oxantel, morantel and thiabedazole.

19. The composition of any one of claims 13 to 18, further comprising an antibiotic.